Alkermes plc (ALKS) jumped 0.59 points or 1.09% on strong buying and was last priced at $54.7 per share. The shares saw huge fund flow intraday; a massive $13.2 million made their way in through the upticks but an even bigger $20.39 million made their way out through downticks. As per the last observation, the net money flow stood at $(-7.19) million and the up/down ratio was found to be 0.65. The shares have seen a weekly value change of 0.66% .A block trade was recorded in the company shares with a net money flow of $(-9.06) million. The composite value of the funds in upticks was $1.08 million and the total value of funds in downticks was $10.14. As can be seen from the data, the block transaction had the up/down ratio of 0.11.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Alkermes plc has lost 1.72% in the last five trading days and dropped 1.58% in the last 4 weeks. Alkermes plc is up 8.51% in the last 3-month period. Year-to-Date the stock performance stands at -1.58%. Alkermes plc (NASDAQ:ALKS) rose 1.09% or 0.59 points on Wednesday and made its way into the gainers of the day. After trading began at $54.45 the stock was seen hitting $54.96 as a peak level and $52.79 as the lowest level. The stock ended up at $54.7. The daily volume was measured at 1,268,003 shares. The 52-week high of the share price is $60.74 and the 52-week low is $27.14. The company has a market cap of $8,313 million.
Company has reported several Insider transactions to the SEC, on Jan 18, 2017, Elliot Ehrich (EVP, R&D & CMO, Alkermes, Inc.) sold 11,983 shares at 54.32 per share price.On Jan 10, 2017, Shane Cooke (President, Alkermes plc) sold 550 shares at 60.27 per share price.On Jan 10, 2017, Mark Stejbach (SVP/Chief Comm Off, Alks Inc) sold 547 shares at 60.27 per share price.
Alkermes Plc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $-0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.05. Analyst had a consensus of $-0.04. The company had revenue of $180.20 million for the quarter, compared to analysts expectations of $186.09 million. The companys revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.